Juno Therapeutics (NASDAQ: JUNO), the Seattle based biotech firm listed on the NASDAQ in December 2014. The IPO raised $256 million, a record in the biotech industry. This success was topped off with the company being valued on its debut above $3 billion, producing the largest introductory market cap of its kind within the biotech industry sphere.

Bliston Asset Management, the Hong Kong based provider of asset management solutions and investment services has been a long-standing supporter of Juno Therapeutics’ business and of the firm’s ability to execute its strategy.

Speaking at it’s Hong Kong based headquarters, Bliston Asset Management’s Chief Technology Analyst was on hand to share his analysis of what the future holds for Juno and it’s investors.

“Bliston Asset Management became aware of Juno as the firm was in its infancy. We recognized that the firm’s research and abilities to implement its findings were poised to deliver groundbreaking solutions in cancer treatment. We invested in Juno and introduced clients leading up to the IPO in December of last year. The results for our investors and for Juno were way above expectations.”

“The IPO results came as a very pleasant surprise for all involved. What is less surprising to us here at Bliston Asset Management is that the stock has continued to attract attention and has performed with impressive results”, continued Bliston Asset Managements Chief Tech Analyst.

Earlier this month it was reported that Celgene (NASDAQ: CELG) purchased over 9 millions shares of Juno at a substantial premium, further increasing the stock price of Juno Therapeutics as indications point towards a pool of untapped potential as the two firm collaborate competencies for future developments.

“The large acquisition of shares made by Celgene simply highlights what we have been telling out clients since the end of last year. And that is the explosive potential Juno has currently stored as the firm continues to make serious steps towards a revolutionary way of treating cancer patients and increasing survival rates across the board.”

As Juno therapies are becoming ever closer to being accessible to the wider market, analyst projections on Wall Street and beyond predict that Juno’s market cap could eventually exceed the $10 million mark.